Michael Hutchinson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6546813/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology, 2011, 69, 292-302.	5.3	8,001
2	A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 354, 899-910.	27.0	2,916
3	Rate of Pregnancy-Related Relapse in Multiple Sclerosis. New England Journal of Medicine, 1998, 339, 285-291.	27.0	1,403
4	Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. New England Journal of Medicine, 2012, 367, 1087-1097.	27.0	1,161
5	Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of postâ€partum relapse. Brain, 2004, 127, 1353-1360.	7.6	573
6	Differential diagnosis of suspected multiple sclerosis: a consensus approach. Multiple Sclerosis Journal, 2008, 14, 1157-1174.	3.0	560
7	Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurology, The, 2009, 8, 254-260.	10.2	430
8	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	7.4	336
9	PROGRESSIVE ENCEPHALOMYELITIS, RIGIDITY, AND MYOCLONUS: A NOVEL GLYCINE RECEPTOR ANTIBODY. Neurology, 2008, 71, 1291-1292.	1.1	324
10	The incidence and significance of anti-natalizumab antibodies. Neurology, 2007, 69, 1391-1403.	1.1	312
11	MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology, 2007, 68, 1390-1401.	1.1	307
12	Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Human Molecular Genetics, 2000, 9, 637-644.	2.9	255
13	New perspectives in the natural history of multiple sclerosis. Neurology, 2010, 74, 2004-2015.	1.1	226
14	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Journal of Neurology, 2009, 256, 405-415.	3.6	193
15	Healthâ€related quality of life in multiple sclerosis: effects of natalizumab. Annals of Neurology, 2007, 62, 335-346.	5.3	172
16	REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. Brain, 2008, 131, 1078-1086.	7.6	163
17	Temporal Discrimination Threshold: VBM evidence for an endophenotype in adult onset primary torsion dystonia. Brain, 2009, 132, 2327-2335.	7.6	134
18	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	10.2	134

#	Article	IF	CITATIONS
19	Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Multiple Sclerosis Journal, 2005, 11, 46-50.	3.0	128
20	Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain, 2009, 132, 1753-1763.	7.6	126
21	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Multiple Sclerosis Journal, 2017, 23, 253-265.	3.0	126
22	Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology, 2007, 68, 1299-1304.	1.1	123
23	Unrecognised symptoms of depression in a community–based population with multiple sclerosis. Journal of Neurology, 2006, 253, 219-223.	3.6	93
24	Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL). Annals of Neurology, 1995, 38, 817-824.	5.3	91
25	Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Therapeutics and Clinical Risk Management, 2007, 3, 259-268.	2.0	90
26	Age at onset as a factor in determining the phenotype of primary torsion dystonia. Neurology, 2004, 63, 1423-1426.	1.1	89
27	Assessing disability progression with the Multiple Sclerosis Functional Composite. Multiple Sclerosis Journal, 2009, 15, 984-997.	3.0	89
28	Leigh disease associated with a novel mitochondrial DNA ND5 mutation. European Journal of Human Genetics, 2002, 10, 141-144.	2.8	88
29	Does natalizumab therapy worsen neuromyelitis optica?. Neurology, 2012, 79, 1065-1066.	1.1	85
30	An epidemiological study of Wilson's disease in the Republic of Ireland Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 298-300.	1.9	76
31	Temporal discrimination thresholds in adult-onset primary torsion dystonia: an analysis by task type and by dystonia phenotype. Journal of Neurology, 2012, 259, 77-82.	3.6	76
32	SPG15, a new locus for autosomal recessive complicated HSP on chromosome 14q. Neurology, 2001, 56, 1230-1233.	1.1	71
33	Pharmacogenomics of responsiveness to interferon IFN-Î ² treatment in multiple sclerosis: A genetic screen of 100 type I interferon-inducible genes. Clinical Pharmacology and Therapeutics, 2005, 78, 635-635.	4.7	71
34	Interferon- \hat{I}^2 1b in the treatment of secondary progressive MS. Neurology, 2001, 57, 1870-1875.	1.1	70
35	Temporal discrimination, a cervical dystonia endophenotype: Penetrance and functional correlates. Movement Disorders, 2014, 29, 804-811.	3.9	70
36	Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison. Current Medical Research and Opinion, 2014, 30, 613-627.	1.9	70

#	Article	IF	CITATIONS
37	Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 572-576.	1.9	68
38	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study. Journal of Neurology, 2013, 260, 2286-2296.	3.6	68
39	Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology, 2012, 259, 898-905.	3.6	66
40	The endophenotype and the phenotype: Temporal discrimination and adultâ€onset dystonia. Movement Disorders, 2013, 28, 1766-1774.	3.9	63
41	Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology, 2015, 84, 1145-1152.	1.1	63
42	The incidence of sudden unexpected death in epilepsy (sudep) in south dublin and wicklow. Seizure: the Journal of the British Epilepsy Association, 1998, 7, 355-358.	2.0	59
43	The prevalence of "pure" autosomal dominant hereditary spastic paraparesis in the island of Ireland. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 43-46.	1.9	59
44	Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland. European Journal of Neurology, 2017, 24, 73-81.	3.3	59
45	Neuroleptic malignant syndrome Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 271-273.	1.9	58
46	Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 317-322.	1.9	56
47	Age-related cognitive decline in hereditary spastic paraparesis linked to chromosome 2p. Neurology, 2000, 54, 1510-1517.	1.1	54
48	Cognitive dysfunction in early multiple sclerosis: a review. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 359-364.	0.5	54
49	Sensory abnormalities in unaffected relatives in familial adult-onset dystonia. Neurology, 2005, 65, 938-940.	1.1	53
50	Sporadic adult onset primary torsion dystonia is a genetic disorder by the temporal discrimination test. Brain, 2011, 134, 2656-2663.	7.6	51
51	Genetic polymorphisms, their allele combinations and IFN-β treatment response in Irish multiple sclerosis patients. Pharmacogenomics, 2009, 10, 1177-1186.	1.3	48
52	Efficacy of delayedâ€release dimethyl fumarate in relapsingâ€remitting multiple sclerosis: integrated analysis of the phase 3 trials. Annals of Clinical and Translational Neurology, 2015, 2, 103-118.	3.7	48
53	A preliminary validation of the brief international cognitive assessment for multiple sclerosis (BICAMS) tool in an Irish population with multiple sclerosis (MS). Multiple Sclerosis and Related Disorders, 2015, 4, 521-525.	2.0	48
54	Further evidence of dementia in <i>SPG4</i> -linked autosomal dominant hereditary spastic paraplegia. Neurology, 2004, 62, 407-410.	1.1	47

#	Article	IF	CITATIONS
55	A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. Multiple Sclerosis Journal, 2012, 18, 1797-1800.	3.0	46
56	Temporal Discrimination: Mechanisms and Relevance to Adult-Onset Dystonia. Frontiers in Neurology, 2017, 8, 625.	2.4	46
57	A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. PLoS ONE, 2015, 10, e0127960.	2.5	45
58	2017 McDonald diagnostic criteria: A review of the evidence. Multiple Sclerosis and Related Disorders, 2018, 24, 48-54.	2.0	44
59	Phenotype of AD-HSP due to mutations in the <i>SPAST</i> gene. Neurology, 2000, 55, 1794-1800.	1.1	43
60	Neural correlates of abnormal sensory discrimination in laryngeal dystonia. NeuroImage: Clinical, 2016, 10, 18-26.	2.7	43
61	Cervical Dystonia: A Disorder of the Midbrain Network for Covert Attentional Orienting. Frontiers in Neurology, 2014, 5, 54.	2.4	42
62	Patient-centered outcomes. Neurology, 2010, 74, S24-35.	1.1	41
63	Bipolar affective disorder prior to the onset of multiple sclerosis. Acta Neurologica Scandinavica, 1993, 88, 388-393.	2.1	40
64	Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study. Multiple Sclerosis Journal, 2014, 20, 253-257.	3.0	40
65	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, genetic homogeneity, and mapping of the locus within a 2-cM interval. American Journal of Human Genetics, 1996, 58, 171-81.	6.2	40
66	Molding the sensory cortex: Spatial acuity improves after botulinum toxin treatment for cervical dystonia. Movement Disorders, 2007, 22, 2443-2446.	3.9	39
67	CADASIL imitating multiple sclerosis: the importance of MRI markers. Multiple Sclerosis Journal, 2002, 8, 430-432.	3.0	38
68	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: MR findings. American Journal of Neuroradiology, 1995, 16, 2115-9.	2.4	38
69	Cervical dystonia following peripheral trauma. Journal of Neurology, 2004, 251, 150-155.	3.6	37
70	Sporadic adult onset dystonia: sensory abnormalities as an endophenotype in unaffected relatives. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 980-983.	1.9	37
71	Economic costs associated with an MS relapse. Multiple Sclerosis and Related Disorders, 2014, 3, 678-683.	2.0	36
72	Paroxysmal torticollis and blepharospasm following bilateral cerebellar Infarction. Journal of Neurology, 2006, 253, 1644-1645.	3.6	35

#	Article	IF	CITATIONS
73	Comparing endophenotypes in adultâ€onset primary torsion dystonia. Movement Disorders, 2010, 25, 84-90.	3.9	35
74	Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM. Expert Opinion on Pharmacotherapy, 2013, 14, 2145-2156.	1.8	34
75	Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel. Multiple Sclerosis and Related Disorders, 2014, 3, 513-519.	2.0	34
76	Linkage of AD HSP and cognitive impairment to chromosome 2p: haplotype and phenotype analysis indicates variable expression and low or delayed penetrance. European Journal of Human Genetics, 1998, 6, 275-282.	2.8	32
77	Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 336-342.	3.0	32
78	<i>OAS1</i> . Neurology, 2010, 75, 411-418.	1.1	31
79	A high-density ERP study reveals latency, amplitude, and topographical differences in multiple sclerosis patients versus controls. Clinical Neurophysiology, 2010, 121, 1420-1426.	1.5	31
80	Pallidal stimulation for cervical dystonia does not correct abnormal temporal discrimination. Movement Disorders, 2013, 28, 1874-1877.	3.9	30
81	Pregnancy in multiple sclerosis Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 1043-1045.	1.9	29
82	Machine Learning EEG to Predict Cognitive Functioning and Processing Speed Over a 2-Year Period in Multiple Sclerosis Patients and Controls. Brain Topography, 2018, 31, 346-363.	1.8	29
83	A proposed modification to the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1095-1100.	3.0	26
84	Unmet needs of multiple sclerosis patients in the community. Multiple Sclerosis and Related Disorders, 2015, 4, 144-150.	2.0	26
85	New versus old: Implications of evolving diagnostic criteria for relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 867-870.	3.0	26
86	Inherited myoclonus-dystonia and epilepsy: Further evidence of an association?. Movement Disorders, 2004, 19, 1456-1459.	3.9	25
87	A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 533-543.	3.0	24
88	Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?. Multiple Sclerosis Journal, 2009, 15, 1528-1531.	3.0	23
89	Using atypical symptoms and red flags to identify non-demyelinating disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 44-48.	1.9	23
90	Incidence of multiple sclerosis in the Republic of Ireland: A prospective population-based study. Multiple Sclerosis and Related Disorders, 2017, 13, 75-80.	2.0	22

#	Article	IF	CITATIONS
91	Disrupted superior collicular activity may reveal cervical dystonia disease pathomechanisms. Scientific Reports, 2017, 7, 16753.	3.3	22
92	The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101863.	2.0	22
93	An evaluation of the role of environmental factors in the disease penetrance of cervical dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 331-335.	1.9	21
94	Sun exposure is an environmental factor for the development of blepharospasm. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 420-424.	1.9	20
95	Only Low Frequency Event-Related EEG Activity Is Compromised in Multiple Sclerosis: Insights from an Independent Component Clustering Analysis. PLoS ONE, 2012, 7, e45536.	2.5	19
96	The Face-Symbol Test and the Symbol-Digit Test are not reliable surrogates for the Paced Auditory Serial Addition Test in multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 599-604.	3.0	18
97	Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double- blind placebo-controlled trial. Trials, 2013, 14, 272.	1.6	18
98	Symptom overlap in anxiety and multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1349-1354.	3.0	18
99	Epidemiology of Wilson's disease in Ireland. Movement Disorders, 2014, 29, 1567-1568.	3.9	18
100	Age-Related Sexual Dimorphism in Temporal Discrimination and in Adult-Onset Dystonia Suggests GABAergic Mechanisms. Frontiers in Neurology, 2015, 6, 258.	2.4	18
101	Preliminary evidence for correlation between PASAT performance and P3a and P3b amplitudes in progressive multiple sclerosis. European Journal of Neurology, 2011, 18, 792-795.	3.3	17
102	Neurodegeneration in multiple sclerosis is a process separate from inflammation: No. Multiple Sclerosis Journal, 2015, 21, 1628-1631.	3.0	17
103	Effects of vitamin D ₃ in clinically isolated syndrome and healthy control participants: A double-blind randomised controlled trial. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731772729.	1.0	17
104	Sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO) in a sibling pair with a homozygous p.A467T <i>POLG</i> mutation. Muscle and Nerve, 2010, 41, 265-269.	2.2	16
105	Truly benign multiple sclerosis is rare: let's stop fooling ourselves - Commentary. Multiple Sclerosis Journal, 2012, 18, 15-15.	3.0	16
106	Dexterity Training Improves Manual Precision in Patients Affected by Essential Tremor. Archives of Physical Medicine and Rehabilitation, 2014, 95, 705-710.	0.9	16
107	Natalizumab improves ambulation in relapsingâ^'remitting multiple sclerosis: results from the prospective <scp>TIMER</scp> study and a retrospective analysis of <scp>AFFIRM</scp> . European Journal of Neurology, 2015, 22, 570-577.	3.3	16
108	Trust the Patient Not the Doctor: The Determinants of Quality of Life in Cervical Dystonia. Frontiers in Neurology, 2020, 11, 991.	2.4	16

#	Article	IF	CITATIONS
109	Social cognition in cervical dystonia: A case-control study. Clinical Parkinsonism & Related Disorders, 2020, 3, 100072.	0.9	15
110	Non-motor features of cervical dystonia: Cognition, social cognition, psychological distress and quality of life. Clinical Parkinsonism & Related Disorders, 2021, 4, 100084.	0.9	15
111	The functional limitations profile may be a valid, reliable and sensitive measure of disability in multiple sclerosis. Journal of Neurology, 1995, 242, 650-657.	3.6	14
112	Change in PASAT performance correlates with change in P3 ERP amplitude over a 12-month period in multiple sclerosis patients. Journal of the Neurological Sciences, 2011, 305, 45-52.	0.6	14
113	Population frequency of HLA haplotypes contributes to the prevalence difference of multiple sclerosis in Ireland. Journal of Neurology, 2005, 252, 1245-1248.	3.6	13
114	Predicting and preventing the future: actively managing multiple sclerosis. Practical Neurology, 2009, 9, 133-143.	1.1	13
115	A budget impact analysis of natalizumab use in Ireland. Irish Journal of Medical Science, 2012, 181, 199-204.	1.5	13
116	Young Women do it Better: Sexual Dimorphism in Temporal Discrimination. Frontiers in Neurology, 2015, 6, 160.	2.4	13
117	The premotor syndrome of cervical dystonia: Disordered processing of salient environmental stimuli. Movement Disorders, 2018, 33, 232-237.	3.9	13
118	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis Journal, 2019, 25, 591-600.	3.0	13
119	Delayed P100-Like Latencies in Multiple Sclerosis: A Preliminary Investigation Using Visual Evoked Spread Spectrum Analysis. PLoS ONE, 2016, 11, e0146084.	2.5	13
120	Neuropsychological assessment in multiple sclerosis: methodological issues and concerns. Multiple Sclerosis Journal, 1996, 2, 57-65.	3.0	12
121	Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. European Journal of Neurology, 2016, 23, 772-779.	3.3	12
122	Linkage to a known gene but no mutation identified: comprehensive reanalysis ofSPG4 HSP pedigrees reveals large deletions as the sole cause. Human Mutation, 2007, 28, 739-740.	2.5	10
123	Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis. Journal of Neurology, 2007, 254, 1547-1554.	3.6	10
124	One can prevent post-partum MS relapses by exclusive breast feeding: Commentary. Multiple Sclerosis Journal, 2013, 19, 1569-1570.	3.0	10
125	A novel <i>CACNA1A</i> mutation associated with adultâ€onset, paroxysmal head tremor. Movement Disorders, 2013, 28, 842-843.	3.9	10
126	Application of virtual reality head mounted display for investigation of movement: a novel effect of orientation of attention. Journal of Neural Engineering, 2016, 13, 056006.	3.5	10

8

#	Article	IF	CITATIONS
127	Dystonia Management: What to Expect From the Future? The Perspectives of Patients and Clinicians Within DystoniaNet Europe. Frontiers in Neurology, 2021, 12, 646841.	2.4	10
128	Safety first, efficacy second in disease modifying therapies. Multiple Sclerosis Journal, 2011, 17, 380-381.	3.0	9
129	Mood disorder affects age at onset of adult-onset cervical dystonia. Clinical Parkinsonism & Related Disorders, 2020, 3, 100049.	0.9	9
130	We Must Talk about Sex and Focal Dystonia. Movement Disorders, 2021, 36, 604-608.	3.9	9
131	Spontaneous intracranial hypotension: case reports and literature review. Irish Journal of Medical Science, 2012, 181, 171-177.	1.5	8
132	Perceived and objective cognitive impairment in newly diagnosed versus established multiple sclerosis: impact of disease duration. Irish Journal of Medical Science, 2021, 190, 1149-1154.	1.5	8
133	Adult onset dystonia: A disorder of the collicular–pulvinar–amygdala network. Cortex, 2021, 143, 282-289.	2.4	8
134	Wilson's disease and the neuroleptic malignant syndrome. Irish Journal of Psychological Medicine, 1990, 7, 138-139.	1.0	7
135	The major cause of multiple sclerosis is environmental: genetics has a minor role - Commentary. Multiple Sclerosis Journal, 2011, 17, 1176-1176.	3.0	7
136	There is no such thing as a mild MS relapse. The mild relapse is an Anglo-Saxon delusion - Commentary. Multiple Sclerosis Journal, 2012, 18, 930-931.	3.0	7
137	CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald Criteria 2010: Commentary. Multiple Sclerosis Journal, 2013, 19, 719-720.	3.0	7
138	Spinal cord MRI should always be performed in clinically isolated syndrome patients: Commentary. Multiple Sclerosis Journal, 2014, 20, 1690-1691.	3.0	7
139	Relapses do not matter in relation to long-term disability: Commentary. Multiple Sclerosis Journal, 2011, 17, 1417-1417.	3.0	6
140	Evoked potentials are of little use in the diagnosis or monitoring of MS: Commentary. Multiple Sclerosis Journal, 2013, 19, 1824-1825.	3.0	6
141	Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Commentary. Multiple Sclerosis Journal, 2014, 20, 1302-1303.	3.0	6
142	A comparison of stimulus presentation methods in temporal discrimination testing. Physiological Measurement, 2017, 38, N57-N64.	2.1	6
143	Practice does not make perfect: Temporal discrimination in musicians with and without dystonia. Movement Disorders, 2017, 32, 1791-1792.	3.9	6
144	A novel GNAL mutation in familial dystonia presenting with childhood tremor and myoclonus. Movement Disorders, 2019, 34, 923-924.	3.9	6

#	Article	IF	CITATIONS
145	In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: Commentary. Multiple Sclerosis Journal, 2013, 19, 29-30.	3.0	5
146	Non-parametric bootstrapping method for measuring the temporal discrimination threshold for movement disorders. Journal of Neural Engineering, 2015, 12, 046026.	3.5	5
147	Temporal discrimination threshold and blink reflex recovery cycle in cervical dystonia – two sides of the same coin?. Parkinsonism and Related Disorders, 2019, 68, 4-7.	2.2	5
148	A clinical, molecular genetics and pathological study of a FTDP-17 family with a heterozygous splicing variant c.823-10G>T at the intron 9/exon 10 of the MAPT gene. Neurobiology of Aging, 2021, 106, 343.e1-343.e8.	3.1	5
149	Phenotypic diversity associated with the mitochondrial m.8313G>A point mutation. Muscle and Nerve, 2009, 40, 648-651.	2.2	4
150	Clinically isolated syndrome: a protected zone for trials of new therapies?. Multiple Sclerosis Journal, 2010, 16, 754-755.	3.0	4
151	Do not treat from CIS onset: evaluate disease course and prognosis first - Commentary. Multiple Sclerosis Journal, 2012, 18, 396-397.	3.0	4
152	Multiparity in women with multiple sclerosis causes less long-term disability: Commentary. Multiple Sclerosis Journal, 2014, 20, 1437-1438.	3.0	4
153	A useful annual review of cognition in relapsing MS is beyond most neurologists – Commentary. Multiple Sclerosis Journal, 2016, 22, 730-732.	3.0	4
154	Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis – Not always self-limiting, fully reversible or predictable. Multiple Sclerosis Journal, 2018, 24, 552-553.	3.0	4
155	Slowed Luminance Reaction Times in Cervical Dystonia: Disordered Superior Colliculus Processing. Movement Disorders, 2020, 35, 877-880.	3.9	4
156	Impact of obstructive sleep apnoea on cognitive function in multiple sclerosis: A longitudinal study. Journal of Sleep Research, 2021, 30, e13159.	3.2	4
157	Longitudinal Followâ€Up of Mood in Cervical Dystonia and Influence on Age at Onset. Movement Disorders Clinical Practice, 2022, 9, 614-618.	1.5	4
158	Natalizumab Therapy of Multiple Sclerosis. Journal of Interferon and Cytokine Research, 2010, 30, 787-789.	1.2	3
159	Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time: Commentary. Multiple Sclerosis Journal, 2012, 18, 1533-1533.	3.0	3
160	DOES JCV ANTIBODY POSITIVITY ENCOURAGE CESSATION OF NATALIZUMAB THERAPY IN MULTIPLE SCLEROSIS?. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.92-e2.	1.9	3
161	Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: Commentary. Multiple Sclerosis Journal, 2013, 19, 1694-1695.	3.0	3
162	Funding CCSVI research is/was a waste of valuable time, money and intellectual energy: Commentary. Multiple Sclerosis Journal, 2013, 19, 861-862.	3.0	3

#	Article	IF	CITATIONS
163	The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary. Multiple Sclerosis Journal, 2015, 21, 1242-1243.	3.0	3
164	Neural Correlates of Abnormal Temporal Discrimination in Unaffected Relatives of Cervical Dystonia Patients. Frontiers in Integrative Neuroscience, 2019, 13, 8.	2.1	3
165	A Study of the Midbrain Network for Covert Attentional Orienting in Cervical Dystonia Patients using Dynamic Causal Modelling. , 2019, 2019, 3519-3522.		3
166	A headset method for measuring the visual temporal discrimination threshold in cervical dystonia. Tremor and Other Hyperkinetic Movements, 2014, 4, 249.	2.0	3
167	Reduced Frequency of Ipsilateral Express Saccades in Cervical Dystonia: Probing the Nigro-Tectal Pathway. Tremor and Other Hyperkinetic Movements, 2018, 8, 592.	2.0	3
168	PONM12 Multifocal motor neuropathy due to infliximab. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e63-e63.	1.9	2
169	Rehabilitation therapy in MS: a short-term, expensive, placebo: Commentary. Multiple Sclerosis Journal, 2012, 18, 1382-1383.	3.0	2
170	Deaths and disability from natalizumab are no longer tolerable: Commentary. Multiple Sclerosis Journal, 2012, 18, 1073-1073.	3.0	2
171	If I had CIS with MRI diagnostic of MS, I would take vitamin D 10,000 IU daily: Commentary. Multiple Sclerosis Journal, 2013, 19, 143-144.	3.0	2
172	The best basic science paper in multiple sclerosis in 2013: Disease specific molecular events in cortical multiple sclerosis lesions. Multiple Sclerosis Journal, 2014, 20, 1817-1818.	3.0	2
173	The best basic science paper in multiple sclerosis in 2014: Citicoline, remyelination and neuroprotection: Commentary. Multiple Sclerosis Journal, 2015, 21, 374-375.	3.0	2
174	Symptomatic therapy in multiple sclerosis: Big pharma should do more – commentary. Multiple Sclerosis Journal, 2015, 21, 982-983.	3.0	2
175	All relapsing multiple sclerosis patients should be managed at a specialist clinic – Commentary. Multiple Sclerosis Journal, 2016, 22, 876-877.	3.0	2
176	Menstrual cycle and the temporal discrimination threshold. Physiological Measurement, 2017, 38, N65-N72.	2.1	2
177	Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia. Journal of Visualized Experiments, 2018, , .	0.3	2
178	Response to "isolated head tremor: A DAT SPECT and somatosensory temporal discrimination study.― Parkinsonism and Related Disorders, 2021, 87, 166-167.	2.2	2
179	Reliability of DNMSQuest as a Screening Tool for Mood Disorders in Cervical Dystonia. Movement Disorders Clinical Practice, 2021, 8, 925-931.	1.5	2
180	A Headset Method for Measuring the Visual Temporal Discrimination Threshold in Cervical Dystonia. Tremor and Other Hyperkinetic Movements, 2020, 4, 249.	2.0	2

#	Article	IF	CITATIONS
181	Intravenous therapy for the treatment of multiple sclerosis. Future Prescriber, 2008, 8, 15-20.	0.1	1
182	Cervical dystonia presenting as a phenocopy in an Irish SCA2 family. Movement Disorders, 2009, 24, 466-467.	3.9	1
183	Obituary. Multiple Sclerosis Journal, 2010, 16, 518-519.	3.0	1
184	We are about to cure MS in the next 10 years, even though we do not know its cause: Commentary. Multiple Sclerosis Journal, 2012, 18, 786-787.	3.0	1
185	The best clinical paper on multiple sclerosis in 2012: Commentary. Multiple Sclerosis Journal, 2013, 19, 522-523.	3.0	1
186	Response to comment on the article by Allen et al. â€~A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers'. Multiple Sclerosis Journal, 2013, 19, 509-509.	3.0	1
187	Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: Commentary. Multiple Sclerosis Journal, 2014, 20, 1169-1170.	3.0	1
188	MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: Commentary. Multiple Sclerosis Journal, 2014, 20, 284-285.	3.0	1
189	Multiple sclerosis relapse phenotype is an important, neglected determinant of disease-outcome: Commentary. Multiple Sclerosis Journal, 2015, 21, 1374-1375.	3.0	1
190	Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis - Commentary. Multiple Sclerosis Journal, 2015, 21, 136-137.	3.0	1
191	Exploring the unknown: electrophysiological and behavioural measures of visuospatial learning. European Journal of Neuroscience, 2016, 43, 1128-1136.	2.6	1
192	Irish neurological association. Irish Journal of Medical Science, 1984, 153, 152-157.	1.5	0
193	Royal academy of medicine in Ireland section of medicine. Irish Journal of Medical Science, 1985, 154, 477-482.	1.5	Ο
194	Irish Neurological association. Irish Journal of Medical Science, 1990, 159, 190-194.	1.5	0
195	Royal Academy of Medicine in Ireland Section of Pathology. Irish Journal of Medical Science, 1997, 166, 267-269.	1.5	Ο
196	POMD05 Temporal discrimination threshold in patients with sporadic adult-onset primary torsion dystonia and their first degree relatives. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e58-e58.	1.9	0
197	PAW29 Multiple sclerosis in Ireland: regional variation in prevalence and vitamin D status. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e31-e31.	1.9	0
198	Controversies in multiple sclerosis: a series of debates. Multiple Sclerosis Journal, 2011, 17, 1170-1170.	3.0	0

#	Article	lF	CITATIONS
199	The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately – Commentary. Multiple Sclerosis Journal, 2012, 18, 561-562.	3.0	0
200	In assessing multiple sclerosis disease activity patient report measures are a waste of time: cut to the MRI scan! – Commentary. Multiple Sclerosis Journal, 2012, 18, 269-270.	3.0	0
201	040â€Electronic neurology referrals: a solution for an overburdened healthcare system?. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.205-e1.	1.9	0
202	Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: Commentary. Multiple Sclerosis Journal, 2012, 18, 1213-1214.	3.0	0
203	The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: Commentary. Multiple Sclerosis Journal, 2012, 18, 1684-1685.	3.0	0
204	THE COST OF A MULTIPLE SCLEROSIS RELAPSE. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A18.3-A18.	1.9	0
205	The best basic science paper on multiple sclerosis in 2012: Commentary. Multiple Sclerosis Journal, 2013, 19, 1130-1131.	3.0	0
206	Electrophysiological and behavioral measures of visuo-motor learning for application in movement disorders. , 2014, 2014, 3533-6.		0
207	We can compare the relative efficacy multiple sclerosis medications by examining the results of independent clinical trials: Commentary. Multiple Sclerosis Journal, 2015, 21, 39-40.	3.0	0
208	The best clinical paper on multiple sclerosis in 2014: Herodotus and Chataway â^' Commentary. Multiple Sclerosis Journal, 2015, 21, 856-857.	3.0	0
209	Integrated multidisciplinary clinics should be the gold standard in managing progressive MS – Commentary. Multiple Sclerosis Journal, 2016, 22, 1130-1131.	3.0	0
210	Modeling the course and outcomes of MS is statistical twaddle—Commentary. Multiple Sclerosis Journal, 2016, 22, 144-145.	3.0	0
211	Marta Elian: Obituary. Multiple Sclerosis Journal, 2017, 23, 370-371.	3.0	0
212	Trials of Licenced RRMS DMTs in Progressive MS. , 2018, , 207-232.		0
213	Characterizing Brain Network Topology in Cervical Dystonia Patients and Unaffected Relatives via Graph Theory. , 2019, 2019, 1694-1697.		0
214	Update: Atypical presentation of a midgut neuroendocrine tumor originally diagnosed as eosinophilic fasciitis. Neurology, 2020, 95, 695-697.	1.1	0
215	Stress and Dystonia. Movement Disorders, 2021, 36, 1794-1794.	3.9	0
216	Current Treatments for Progressive Multiple Sclerosis: Disease-Modifying Therapies. , 2013, , 187-219.		0

13